Mackenzie Financial
ESPR

Mackenzie Financial’s Esperion Therapeutics ESPR Stock Holding History

Mackenzie Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-659,120
Closed -$1.81M – 1599
2026
Q1 		$1.81M Buy
659,120
+322,128
+96% +$1.02M ﹤0.01% 947
2025
Q4 		$1.24M Buy
336,992
+64,034
+23% +$207K ﹤0.01% 999
2025
Q3 		$723K Buy
272,958
+261,258
+2,233% +$505K ﹤0.01% 1156
2025
Q2 		$11.5K Sell
11,700
-111,415
-90% -$112K ﹤0.01% 1687
2025
Q1 		$177K Sell
123,115
-20,137
-14% -$37.1K ﹤0.01% 1537
2024
Q4 		$315K Buy
143,252
+76,965
+116% +$180K ﹤0.01% 1362
2024
Q3 		$109K Buy
66,287
+31,033
+88% +$62.7K ﹤0.01% 1472
2024
Q2 		$78.3K Buy
35,254
+18,036
+105% +$42.4K ﹤0.01% 1456
2024
Q1 		$46.1K Buy
17,218
+3,827
+29% +$9.3K ﹤0.01% 1490
2023
Q4 		$40K Sell
13,391
-19,227
-59% -$24.9K ﹤0.01% 1458
2023
Q3 		$31.5K Buy
32,618
+5,341
+20% +$7.73K ﹤0.01% 1438
2023
Q2 		$38.7K Sell
27,277
-60,060
-69% -$83.9K ﹤0.01% 1475
2023
Q1 		$139K Buy
87,337
+19,494
+29% +$101K ﹤0.01% 1380
2022
Q4 		$423K Buy
+67,843
New +$485K ﹤0.01% 984

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Mackenzie Financial's ESPR Position: Q2 2026 in Review

Mackenzie Financial sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 659,120 shares — an estimated $1.81M sold.

Mackenzie Financial first reported a position in ESPR in Q4 2022 and held it in 14 quarters. The position peaked at $1.81M in Q1 2026. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Mackenzie Financial reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mackenzie Financial sold 659,120 Esperion Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Mackenzie Financial first reported a position in Esperion Therapeutics in Q4 2022 and held it in 14 quarters.
  • Mackenzie Financial's Esperion Therapeutics position peaked at $1.81M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.